Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SYNTARA LIMITED Director's Dealing 2009

Oct 21, 2009

65830_rns_2009-10-21_5f21a6f9-28d9-4f3f-9347-0f54f0c59658.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity PHARMAXIS LTD ABN 75 082 811 630

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Alan Duncan Robertson
Date of last notice 24 October 2008

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct Direct
Nature of indirect interest
(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest.
Date of change 21 October 2009
No. of securities held prior to change Options over ordinary shares: 2,880,000
Class Unlisted options
Number acquired 21 October 2009: 200,000 options
Number disposed Nil
Value/ConsiderationNote: If consideration is non-cash, provide details andestimated valuation Granted under Pharmaxis Employee Option Plan fconsideration. Value of $293,200 using a Black Scoption pricing model. or nilholes
No. of securities held after change Options over ordinary shares: 3,080,000
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Nature of changeExample: on-market trade, off-market trade, exercise ofoptions, issue of securities under dividend reinvestment plan,participation in buy-back Grant of options under Pharmaxis Employee OptionPlan. The options were granted on 21 October 2009following approval at the 2009 annual general meetingof the Company and as advised to the ASX on 23 June2009 and 22 October 2009.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details andan estimated valuation
Interest after change
  • See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002